Evidence map›Paper›PMID 24710341›Full record

Trial reportPloS one2014

Impact of acetazolamide and CPAP on cortical activity in obstructive sleep apnea patients.

Katrin Stadelmann, Tsogyal D Latshang, Yvonne Nussbaumer-Ochsner, Leila Tarokh, Silvia Ulrich, Malcolm Kohler, Konrad E Bloch, Peter Achermann

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00714740 phase4completednot on this map

Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

TypeinterventionalSponsorUniversity of ZurichRan2008 to 2008Enrolled49ConditionsObstructive Sleep Apnea SyndromeArmsacetazolamide
NCT00928655 phase4completednot on this map

Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

TypeinterventionalSponsorUniversity of ZurichRan2009 to 2009Enrolled51ConditionsObstructive Sleep Apnea SyndromeArmsacetazolamide, nocturnal continuous positive airway pressure, placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Katrin StadelmannInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
Tsogyal D LatshangPulmonary Division, University Hospital Zurich, Zurich, Switzerland.
Yvonne Nussbaumer-OchsnerPulmonary Division, University Hospital Zurich, Zurich, Switzerland.
Leila TarokhInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland; University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
Silvia UlrichPulmonary Division, University Hospital Zurich, Zurich, Switzerland.
Malcolm KohlerZurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland; Pulmonary Division, University Hospital Zurich, Zurich, Switzerland.
Konrad E BlochZurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland; Pulmonary Division, University Hospital Zurich, Zurich, Switzerland.
Peter AchermannInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
University Hospital of Zurich · CHSwiss Integrative Center for Human Health · CHUniversity of Zurich · CHUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectives1) To investigate the impact of acetazolamide, a drug commonly prescribed for altitude sickness, on cortical oscillations in patients with obstructive sleep apnea syndrome (OSAS). 2) To examine alterations in the sleep EEG after short-term discontinuation of continuous positive airway pressure (CPAP) therapy.

designData from two double-blind, placebo-controlled randomized cross-over design studies were analyzed.

settingPolysomnographic recordings in sleep laboratory at 490 m and at moderate altitudes in the Swiss Alps: 1630 or 1860 m and 2590 m. PATIENTS: Study 1: 39 OSAS patients. Study 2: 41 OSAS patients.

interventionsStudy 1: OSAS patients withdrawn from treatment with CPAP. Study 2: OSAS patients treated with autoCPAP. Treatment with acetazolamide (500-750 mg) or placebo at moderate altitudes. MEASUREMENTS AND

resultsAn evening dose of 500 mg acetazolamide reduced slow-wave activity (SWA; approximately 10%) and increased spindle activity (approximately 10%) during non-REM sleep. In addition, alpha activity during wake after lights out was increased. An evening dose of 250 mg did not affect these cortical oscillations. Discontinuation of CPAP therapy revealed a reduction in SWA (5-10%) and increase in beta activity (approximately 25%).

conclusionsThe higher evening dose of 500 mg acetazolamide showed the "spectral fingerprint" of Benzodiazepines, while 250 mg acetazolamide had no impact on cortical oscillations. However, both doses had beneficial effects on oxygen saturation and sleep quality.

Indexed as

Continuous Positive Airway PressureAcetazolamideAgedAltitude SicknessCarbonic Anhydrase InhibitorsCerebral CortexCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedPolysomnographySleep Apnea, ObstructiveAcetazolamideCarbonic Anhydrase Inhibitors

Identifiers

PMID24710341
PMCPMC3977962
OpenAlexW2060254089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.